125 Evaluation of Patients Experience of Receiving Immunotherapy (IO)

Abstract

Introduction Following NICE approval of Atezolizumab as a subcutaneous (SC) injection, some NHS Chemo-Day Units (CDU) have switched Atezolizumab from intravenous to SC formulation. In this project, we evaluate the current needs and experience of patients receiving intravenous immunotherapy and whether there is a clinical need for a One Stop SC IO outpatient service. Methods Patient experience surveys were developed and administered to patients undergoing mono-IO from August to October 2024. An audit on 'fit note' to 'needle time' was conducted during a similar period. Results 20 surveys were conducted on patients receiving all types of mono-IO therapy: * 35% of patients feel the frequency of hospital visits affect their life; 26% feel it affect their family's life. * 25% of patients feel time spent in hospital for IO affecting their life; 35% feel it affect their family's life. * 45% of patients attend appt and treatment with family and carers. * 55% of patients spend 1-3 hours, one way, travelling to hospital for appointment. * 31% of patients spend?>2 hours at CDU on the day of IO. 39 treatment episodes were audited, (excluding C1), to identify 'fit note' to 'needle time': * Current service provides a multi-step process whereby 97% of patients are reviewed more than 3 days prior to receiving IO. Conclusion This baseline audit identified areas for improvement within IO service. Patient Experience Survey indicated a degree of impact to patients and families from receiving IO. The distance of travel, multiple trips to hospital, waiting time on the day of appointment and treatment are parts of the causations. Therefore, a One-Stop IO out-patient service could be the solution to improve service delivery and patient experience. Disclosure No significant relationships.